ArticleGastroenterology2005
Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome.
Article in Gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 79 citations in OpenAlex.
- The Dual Roles of Gut Microbiota in Biliary Atresia: Mechanisms, Biomarker Potential, and Therapeutic Implications.Microorganisms · 2026Review
- Disruption of Hepatic Sinusoidal Homeostasis Leads to Hepatopulmonary Syndrome.Journal of cellular and molecular medicine · 2025Review
- Endothelin Signaling Mediates Biliary-Endothelial Crosstalk in Primary Sclerosing Cholangitis.Cellular and molecular gastroenterology and hepatology · 2023Article
- Quercetin ameliorates acute lung injury in a rat model of hepatopulmonary syndrome.BMC complementary medicine and therapies · 2022Article
- Hepatopulmonary syndrome.JHEP reports : innovation in hepatology · 2022Review
- Cellular crosstalk during liver regeneration: unity in diversity.Cell communication and signaling : CCS · 2022Review
- Article
- The TGFβ1 Receptor Antagonist GW788388 Reduces JNK Activation and Protects Against Acetaminophen Hepatotoxicity in Mice.Toxicological sciences : an official journal of the Society of Toxicology · 2019Article
- Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.Hepatology (Baltimore, Md.) · 2018Review
- Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies.International journal of molecular sciences · 2018Review
- Review article: Update on current and emergent data on hepatopulmonary syndrome.World journal of gastroenterology · 2018Review
- The balancing act of the liver: tissue regeneration versus fibrosis.The Journal of clinical investigation · 2018Review
- Cirrhosis and autoimmune liver disease: Current understanding.World journal of hepatology · 2016Review
- Hepatopulmonary Syndrome and Liver Transplantation: A Recent Review of the Literature.Journal of clinical and translational hepatology · 2016Review
- Hepatopulmonary Syndrome.Digestive diseases and sciences · 2015Review
- Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.World journal of gastroenterology · 2014Review
- Endothelin-1 activation of the endothelin B receptor modulates pulmonary endothelial CX3CL1 and contributes to pulmonary angiogenesis in experimental hepatopulmonary syndrome.The American journal of pathology · 2014Article
- The relationship between hepatopulmonary syndrome and altitude.Canadian journal of gastroenterology & hepatology · 2014Article
- The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.American journal of physiology. Gastrointestinal and liver physiology · 2014Article
- Advances in cholangiocyte immunobiology.American journal of physiology. Gastrointestinal and liver physiology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND &
aimsHepatic production and release of endothelin 1 plays a central role in experimental hepatopulmonary syndrome after common bile duct ligation by stimulating pulmonary endothelial nitric oxide production. In thioacetamide-induced nonbiliary cirrhosis, hepatic endothelin 1 production and release do not occur, and hepatopulmonary syndrome does not develop. However, the source and regulation of hepatic endothelin 1 after common bile duct ligation are not fully characterized. We evaluated the sources of hepatic endothelin 1 production after common bile duct ligation in relation to thioacetamide cirrhosis and assessed whether transforming growth factor beta1 regulates endothelin 1 production.
methodsHepatopulmonary syndrome and hepatic and plasma endothelin 1 levels were evaluated after common bile duct ligation or thioacetamide administration. Cellular sources of endothelin 1 were assessed by immunohistochemistry and laser capture microdissection of cholangiocytes. Transforming growth factor beta1 expression and signaling were assessed by using immunohistochemistry and Western blotting and by evaluating normal rat cholangiocytes.
resultsHepatic and plasma endothelin 1 levels increased and hepatopulmonary syndrome developed only after common bile duct ligation. Hepatic endothelin 1 and transforming growth factor beta1 levels increased over a similar time frame, and cholangiocytes were a major source of each peptide. Transforming growth factor beta1 signaling in cholangiocytes in vivo was evident by increased phosphorylation and nuclear localization of Smad2, and hepatic endothelin 1 levels correlated directly with liver transforming growth factor beta1 and phosphorylated Smad2 levels. Transforming growth factor beta1 also stimulated endothelin 1 promoter activity, expression, and production in normal rat cholangiocytes.
conclusionsCholangiocytes are a major source of hepatic endothelin 1 production during the development of hepatopulmonary syndrome after common bile duct ligation, but not in thioacetamide-induced cirrhosis. Transforming growth factor beta1 stimulates cholangiocyte endothelin 1 expression and production. Cholangiocyte-derived endothelin 1 may be an important endocrine mediator of experimental hepatopulmonary syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.